Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Non Operating Income came in at $1.3 million in Q1 2026, up 11.76% YoY from $1.1 million in Q1 2025, and up 115.03% on a QoQ basis from -$8.5 million in Q4 2025.
Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Non Operating Income data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Non Operating Income rose 11.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 104.09% YoY) and the FY2025 annual result came in at -$5.2 million, down 115.43% from the prior year.
- Non Operating Income advanced to $1.3 million in Q1 2026, from -$8.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $108.0 million in Q2 2024 to a low of -$21.9 million in Q4 2024.
- A 5-year average of $6.5 million and a median of -$898000.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 7094.12% — and 2024, when it soared 10529.05%.
- Tracing AVTX's Non Operating Income over 5 years: stood at -$949000.0 in 2022, then surged by 45.31% to -$519000.0 in 2023, then slumped by 4122.35% to -$21.9 million in 2024, then jumped by 61.05% to -$8.5 million in 2025, then jumped by 115.03% to $1.3 million in 2026.
- The last three Non Operating Income figures came in at $1.3 million (Q1 2026), -$8.5 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -4.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.82 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | -8.54 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | -21.91 Mn |
| Sep 30, 2024 | 35.88 Mn |
| Jun 30, 2024 | 108.05 Mn |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -519,000.00 |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -1.04 Mn |
| Mar 31, 2023 | -949,000.00 |
| Dec 31, 2022 | -949,000.00 |
| Sep 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -1.15 Mn |
| Mar 31, 2022 | -1.19 Mn |
| Dec 31, 2021 | -1.18 Mn |
| Sep 30, 2021 | -1.00 Mn |